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The purpose of the study conducted was to know the 
extent of protection over the cancer associated metabolic 
syndrome development after administration of ethanol and 
aqueous extracts of Drosera peltata J.E.Sm against Dalton’s 
ascites lymphoma (DAL) and Ehrlich's Ascites Carcinoma (EAC) 
bearing mice. Animals were divided into thirteen groups with a 
normal control, EAC control, DAL control, two groups with 
standard drug 5-Flurouracil 20mg/kg+ DAL & EAC and eight 
groups with 250 and 500mg/kg of ethanol and aqueous extracts 
of D.peltata J.E.Sm + EAC & DAL, for respective cell lines. After 
24h of both tumor cell inoculations, animals were treated with 
extracts, once in a day for 14 days continuously. The indicators 
for the development of metabolic syndrome such as changes in 
blood glucose, serum hormone and lipid profile were found with 
both cell line bearing mice. Both ethanol and aqueous extracts of 
D.peltata J.E.Sm at doses of 250 and 500mg/kg significantly 
reduced the elevated blood glucose, hormonal and lipid profile 
changes. These results confirmed that ethanol and aqueous 
extracts can stabilize the tumor induced hormonal, blood glucose 
and lipid profile changes in tumor bearing mice. This effect might 
be due to the presence of pharmacologically active phyto-
constituents in extracts. 
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INTRODUCTION 
The components of metabolic syndrome 
(MS) was described by National Cholesterol 
Education Program/Adult Treatment Panel III 
(NCEP-ATP III), the World Health 
Organization (WHO), the International 
Diabetes Federation (IDF)  and the American 
Association of Clinical Endocrinologists 
(AACE) where is associated with type 2 
diabetes mellitus, polycystic ovarian disease, 
non-alcoholic fatty liver disease (NAFLD), and 
possibly some cancers (Pooja et al., 2009). 
Different study reports supported that the MS, 
or its components, might play an important 
role in the ethiology and progression of certain 
cancer types and a worse prognosis for some 
cancers such as breast, endometrial, colorectal, 
pancreatic, hepatic and renal cancer                  
(Sandra Braun et al., 2011). MS is a bunch of                     
adiposity, hyperglycaemia, hypertension and 
dyslipidaemia. The additive or synergistic 
effects of the above components are key 
factors for cancer development and cancer 
related mortality. Abnormal body weight, 
inflammation and insulin resistance are 
interconnected where insulin resistant obese 
individuals are associated with secretion of  
tumor necrosis factor alpha (TNF-α) from 
adipose tissue which affect the  intracellular 
insulin signal cascade (hyperglycaemia). It is 
also associated with elevation in free fatty 
acid levels (dyslipidaemia), decrease in 
adiponectin levels, inhibition of peroxisome 
proliferator-activated receptor gamma by 
TNF-α and interleukin (IL)-1 stimulated 
with nuclear factor kappa B (NF-κB) 
(Uzunlulu et al., 2016). This leads to an 
abnormal variation of energy metabolism in 
cancer survivors and has become a hallmark 
syndrome for them. To overcome this 
increased energy requirements, tumor cells 
secrete cytokines/factors inducing muscle and 
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fat degradation in cancer patients, a condition 
known as cancer cachexia which is the main 
cause of death, even in patients undergone  
drug treatments. Drug therapy with targeting 
devoid of cancer cachexia development is 
under research. A study reported that ketogenic 
diet supplied to cachectic phenotype altered 
metabolic condition, reduced tumor growth 
and inhibition of muscle and body weight loss 
(Surendra, et al., 2014). 
The main approach for the treatment 
and prevention of MS in cancer is change in 
lifestyle and the next step is to treat the 
individual with their clinical manifestations 
(Pooja et al., 2009). The epidemiologic studies 
of MS to cancer are scarce and the reported 
study states that low levels of HDL are related 
with an augmented risk of malignancy. Similarly 
decreased level of serum low density lipoprotein 
is associated with the development of 
haematological cancer. High level triglyceride in 
serum is associated with increased risk of 
postmenopausal breast cancer and prostate 
cancer (Emily and Derek, 2013). Currently, 
there is no drug therapy for the symptomatic 
treatment of MS to cancer or as an entire 
disease. However widespread research endures 
to focus on this and have published lot of 
articles per year. These problems can be solved 
by naturopathic plant drug treatment where the 
treatment will help for the maintenance of 
normal metabolism, reduction of side effects 
and enhancement of body's immune system 
(Sanyal et al., 2002). In Ayurveda, the treatment 
comprises the use of entire plant extracts either 
alone or as a mixture of numerous plant 
extracts for better efficacy and reduction in 
toxicity. These herbal preparations contain 
variety of active constituents, which may 
function synergistically, causing therapeutic 
benefits and dropping the risks of adverse 
effects (Prachi et al., 2007). A plant with high 
flavonoid content with well-known anticancer 
property might be the best drug for the 
treatment of cancer associated MS (Raju et al., 
2013a). An example for such a plant is D. peltata 
J.E.Sm, Droseraceae, which is a cosmopolitan, 
insectivorous plant. Among  the 170 species, 
three plants are found in India, namely                  
D. peltata J.E.Sm, D. indica L., and D. burmannii. 
Swarnabhasma is an Ayurvedic preparation 
which contains all the above three                   
Drosera  species. The genus   Drosera                        contains  
plumbagin, naphthoquinones and flavonoids. It 
has been reported that it can be used for the 
treatment of bronchial disorders, diabetes 
mellitus, dyslipidaemia, tuberculosis, spasms, 
infections by various microbes, leprosy, malaria, 
cancer, leishmaniasis, fertility problems, CVS 
disorders such as arteriosclerosis, phthisis and 
also have immunomodulatory effect. The 
quercetin present in this plant is active against 
cancer (Raju et al., 2013b). From D. peltata 
J.E.Sm, 11 compounds were elucidated as 
isoshinanolone-4-O-beta-D-glucoside, isoshina-
nolone, epi-isoshinanolone, plumbagin, drose-
rone, droserone-5-O-glucoside, quercetin, ka-
empferol, gossypetin-8-O-glucoside, 3,3'-dime-
thoxy ellagic acid, and ellagic acid. Extracts of 
plumbagin from Plum-bagineae and Drosera-
ceae have long traditions of use in folk 
medicines in China and other Asian countries 
for the treatment of cancer, rheumatoid 
arthritis, dysmenorrhea and contusion of 
extremities (Robert et al., 2012). This present 
study is aimed to know the effect of ethanol 
and aqueous extract D. peltata J.E.Sm on 
protection over the cancer associated metabolic 
syndrome developed in tumor bearing mice. 
 
MATERIALS AND METHODS 
Plant materials 
The entire plant of D. peltata J.E.Sm. was 
collected from Munnar hills, Kerala, India. 
Prof. K. Madhava Chetty, Taxonomist from 
S.V. University Andhra Pradesh, India,    
identified and authenticated this plant. 
 
Preparation of the extracts 
Alcohol extract 
 The weighed, shade dried powdered 
plant materials were extracted with 90 % v/v 
ethanol in a Soxhlet extraction apparatus. The 
concentrated extract was suspended in distilled 
water for experimental use as EEDP (Ethanol 
extract of D. peltata J.E.Sm). 
Aqueous extract 
The marc which was obtained at the end 
of ethanol extraction was soaked in water for 
48 hours to get the aqueous extract of D. 
peltata. This was concentrated under reduced 
pressure and was used as AEDP (Aqueous 
extract of D. peltata J.E.Sm). 
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The ethanol (EEDP) and aqueous 
(AEDP) extracts of D. peltata were stored in air 
tight containers for further study. 
 
Induction of tumor using DAL and EAC 
cells 
Dalton Ascites Lymphoma (DAL) and 
Ehrlich's Ascites Carcinoma (EAC) cells were 
supplied by Amala Cancer Research Center, 
Thrissur, Kerala, India. The cells were main-
tained in vivo in Swiss albino mice by intraperi-
toneal transplantation. The tumor cells were 
injected intraperitoneally (2x106 cells per mouse) 
to animals of all groups except the first group. 
 
Determination of anticancer activity   
For the anticancer activity study (Raju et 
al., 2013a) Swiss Albino mice weighing 20-25g 
were kept in identical laboratory condition and 
were fed with standard pellet diet and water ad. 
libitum. Study protocol was approved by the 
Institution Animal Ethical Committee (Protocol. 
No: A. Raju 0903PH2254/JNTUH 2009). They 
were divided into thirteen groups (G1-G13) viz. 
Normal group(G1), DAL control group (G2), 
EAC control (G3), DAL+ 20mg/kg of 5-
Fluorouracil treated group (G4), EAC+ 20mg/kg 
of 5-Fluorouracil treated group (G5), DAL 
+250mg/kg EEDP treated (G6), DAL 
+500mg/kg EEDP treated (G7), EAC +250 
mg/kg EEDP treated (G8), EAC +500mg/kg 
EEDP treated (G9), DAL +250 mg/kg AEDP 
treated (G10), DAL +500mg/kg AEDP treated 
(G11), EAC +250mg/kg AEDP treated (G12), 
EAC +500mg/kg AEDP treated (G13) with  six 
mice each, were used for the study.  The DAL 
and EAC cells were injected intraperi-toneally 
(2X106 cells/mouse) to all groups of animals 
except G1. On the second day the animals of G4 
and G5 were treated with 5- fluorouracil 
(20mg/kg, i.p), G6 to G9 were treated with 250, 
500mg/kg of EEDP and G10 to G13 with 250, 
500mg/kg of AEDP orally. The treatment was 
continued for 14 days. G1 was treated with 
vehicle. On day 15, blood was withdrawn by 
retro orbital plexus method, the mice were 
sacrificed and the following parameters were 
checked.  
 
Assessment of antitumor activity 
Tumor growth and development in DAL 
and EAC bearing mice are assessed by derived 
parameters such as body weight, packed cell 
volume (PCV),  tumor cell count (viable),   Mean  
survival time (MST), and Percentage increase in 
life span (% ILS). On day 15, from the 
abdomen inoculated tumor cell lines were 
collected in a centrifuge tube and packed cell 
volume was measured.  Viable cell count from 
suspension containing 100µL of cells were 
stained with 400µL 0.4% Trypan Blue using a 
hemocytometer. The live, unstained cells (live 
cells do not take up Trypan Blue) were counted 
in one set of 16 squares using a hand tally 
counter.  
 
Assay of hormones 
Mature female (virgin) Swiss Albino 
mice weighing 20-25g were used for the assay 
of hormone (Rezvanfar et al., 2008).  LH, FSH, 
E2 and progesterone levels were measured from 
the blood serum (Anup et al., 2007). 
 
Lipid profile, blood glucose and liver 
enzymes 
Blood glucose, cholesterol, triglyceride, 
HDL cholesterol were estimated (Feinleib, 
1983) using kits from Agappe Diagnostics, 
Kerala, India. Similarly estimation of Aspartate 
Aminotransferase (AST), Alanine Aminotrans-
ferase (ALT), Alkaline Phosphatase (ALP) 
Lactate Dehydrogenase (LDH) were also 




The results were expressed as mean ± 
S.E.M. The evaluation of the data was done 
using one way ANOVA followed by Newman-
Keul’s multiple comparison test; p< 0.05 
implied significance. 
 
RESULT AND DISCUSSION 
The effect of EEDP and AEDP on 
tumor growth and development in DAL 
bearing mice (Table I), with respect to             
packed cell volume, cell counts (viable) and                
% ILS. Both the doses of extracts and 5 FU, 
significantly (p<0.001) restored the body 
weight and cell count and was compared          
with tumor control group mice. Similarly %  
ILS and MST were increased in extract 
treatment   groups  and  was  compared   with                
Raju Asirvatham 
 
Volume 27 Issue 4 (2016) 206 
the tumor control group. The level of PCV  
was increased in tumor control mice and   was  
normalised    by   extract   treatment.  
 The data are mentioned as mean± S. E. 
M. n = 6. The data was evaluated by one way 
ANOVA by using Newman-Keul’s multiple 
comparison test. a- p<0.001, compared to             
the tumor control group. Effective role of 
EEDP and AEDP on tumor growth and 
development  in  EAC  bearing  mice (Table II).  
Oral administration of 250, 500mg/kg of 
EEDP  and AEDP significantly (p<0.001) 
increased the MST and % ILS of EAC bearing 
mice whereas MST and % ILS were decreased 
in second group mice. Similarly, there was an 
increase in body weight, PCV and viable cell 
count in tumor control group mice and were 
significantly (p<0.001) decreased to near to 
normal by 14 days continuous administration of 
250, 500mg/kg of EEDP and AEDP.  








ILS (%) PCV (mL) 
Viable cell count  
(106 cells /mouse) 
Normal 22.5±0.81 40 100 - - 
DAL control 35.43±1.34 14±1.14 36±2.81 30.56±0.54 7.16±1.45 
DAL+5FU 
(20mg/kg) 
22.63±0.75 36.6±0.9 91.5±2.32 18.46±0.25 0.68±0.12 
DAL+EEDP 
250mg/kg 
23.7±0.8a 35.4±0.5a 88.5±1.28a 25.6±1.5a 0.48±0.11a 
DAL+EEDP 
500mg/kg 
22.1±0.68a 39.4±0.5a 98±0.94a 27.02±0.65a 0.3±0.11a 
DAL+AEDP 
250mg/kg 
26.3±1.03a 32.8±0.86a 82±2.15a 27.3±0.66a 2.54±0.71a 
DAL+AEDP 
500mg/kg 
24.25±0.42a 35±0.55a 86±0.61a 28.01±0.48a 1.9±0.18a 
 
 
These experimental outcomes indicated that the two doses of EEDP and AEDP exhibited inhibition of 
tumor cell growth on tumor cell inoculated mice. 
 







ILS (%) PCV (mL) 
Viable cell count  
(106 cells /mouse) 
Normal 22.55±1 40 100 - - 
EAC control 37.98±1.79 11.4±0.5 28.5±1.28 30.56±0.54 10.6±1.58 
EAC +5FU 
(20mg/kg) 
22.1±0.89 37.8±0.6 94.5±1.66 18.46±0.25 0.76±0.17 
EAC +EEDP 
250mg/kg 
24.35±1.6a 35±0.5 a 87.5±1.37a 25.6±1.5 a 0.44±0.1 a 
EAC +EEDP 
500mg/kg 
23.3±0.29 a 36.8±0.86a 92±2.15 a 27.02±0.65 a 0.32±0.09 a 
EAC +AEDP 
250mg/kg 
25.3±0.29 a 35±1 a 87.5±2.5 a 27.3±0.66 a 2.52±0.5 a 
EAC +AEDP 
500mg/kg 
24.1±0.7 a 35.2±0.37a 88±0.94 a 28.01±0.48 a 1.82±0.17 a 
 
The data are expressed as mean± S.E.M. n = 6. The data was analyzed by one way ANOVA followed by 
Newman-Keul’s multiple comparison test. a- p<0.001, compared to the tumor control group. 
 
Modulatory Effect of Drosera peltata J.E.Sm 
Volume 27 Issue 4 (2016) 207 
An altered lipid profile and blood 
glucose level was found in EAC bearing mice 
(Table II). The continuous oral treatment        
for  14 days with 250, 500mg/kg  of EEDP    
and AEDP in EAC bearing mice, restored         
the altered parameters, i.e; the serum 
cholesterol, HDL cholesterol and LDL 
cholesterol and showed significant (p<0.001) 
decrease in EAC control mice. In that, serum 
triglycerides and blood glucose values were 
significantly elevated in EAC control mice and 
were brought back to normal by the extract 
treatments, 250 and 500 mg/kg of EEDP and 
AEDP. 
Table III. Effect of EEDP and AEDP on lipid profile and blood glucose on EAC tumor cell 
bearing mice 
 
    Groups 
                 











Normal 142.89±2.19 92.87±2.49 39.78±0.21 119.73±1.09 110.6±1.23 
EAC Control 107.03±1.22 124.63±0.79 27.73±0.71 81.45±2.66 214.3±4.45 
EAC + 5FU 
(20mg/kg) 
118.46±0.92 88.23±1.19 35.33±1.08 116.98±0.9 130.1±1.9 
EAC + EEDP 
(250mg/kg) 
130.5±0.2a 99.13±1.39a 32.08±0.64a 117.98±1.3a 148.4±2.1a 
EAC + EEDP 
(500mg/kg) 
135.43±1.43a 93.6±1.93a 37.73±0.75a 127.5±0.57a 127.4±2.7 a 
EAC + AEDP 
(250mg/kg) 
125.9±1.7a 114.35±2.0a 34.53±0.52a 106.8±1.14a 180.7±8.1b 
EAC + AEDP 
(500mg/kg) 
134.98±1.52a 104.18±0.9a 33.85±0.82a 113.7±1.45a 137.2±5.2 a 
 
 
Table IV. Effect of EEDP and AEDP on lipid profile and blood glucose on DAL tumor cell 
bearing mice 
 
      Groups 
 











Normal 154.45±5.12 128.6±4.37 36.65±0.39 119.3±3.3 110.6±1.23 
DAL Control 122.68±3.7 206.06±3.31 23.55±0.81 69.3±3.1 263.7±8.3 
DAL + 5FU 
(20mg/kg) 
145±0.95 158.75±2.15 34.8±1.13 119.78±1.2 142.5±2.5 
DAL + EEDP 
(250mg/kg) 
137.08±1.27b 168.6±1.4a 32.58±0.9 a 120.15±0.74a 128.6±3.4a 
DAL + EEDP 
(500mg/kg) 
149.9±1.87a 153.86±1.3a 36.13±0.88 a 116.3±0.9a 117.5±2.6 a 
DAL + AEDP 
(250mg/kg) 
130.58±3.69d 175.4±0.8 a 30.53±0.51a 107.55±2.29 a 193.4±1.2b 
DAL + AEDP 
(500mg/kg) 
146.43±0.63a 170.95±1.5 a 32.7±1.01a 112.9±1.59a 149.3±5.8 a 
 
The data is mentioned as mean ±  S. E. M.  n = 6. The data was evaluated by one way ANOVA by using 
Newman-Keul’s multiple comparison test.a-p<0.001, compared to the tumor control group, b- p<0.01, 
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Table IV shows the blood glucose and 
lipid profile of DAL bearing mice, where the 
cholesterol, HDL and LDL level showed 
significant (p<0.001) decrease in DAL control 
mice and were restored by the doses of 250, 
500mg/kg of EEDP and AEDP, whereas, the 
serum triglyceride and blood glucose values 
were significantly elevated in DAL control mice 
and were brought back to normal by the extract 
treatment. However, 250mg/kg of AEDP was 
less significant (P<0.05) in normalization of 
cholesterol level. 
The continuous oral administration for 
14 days with 250 and 500 mg/kg of EEDP and 
AEDP restored the hormone level near to 
normal in female virgin mice bearing EAC cell 
line. The altered hormonal levels in virgin 
(Table V), where 250mg/kg of AEDP and 
AEDP were not significant (P>0.05) in 
restoration of LH and less significant (P<0.01) 
to FSH and E2. Also 500mg/kg of EEDP and 
AEDP showed less significant (P<0.01) effect 
on LH level in EAC bearing mice. Lower dose 













Normal 21.45±1.17 10±0.39 24.9±0.29 18.55±0.17 
EAC Control 29.55±0.78 4.65±0.15 7.45±0.15 6.63±0.33 
EAC+ 5FU 
(20mg/kg) 
19.83±1.6 7.98±0.45 22.55±1.15 16.8±0.64 
EAC+ EEDP 
(250mg/kg) 
25.87±1.8 d 6.28±0.13b 14.8±1.36a 12.8±0.23 a 
EAC+ EEDP 
(500mg/kg) 
24.63±0.23c 8.17±0.27 a 23.73±0.5 a 17.73±0.15 a 
EAC+ AEDP 
(250mg/kg) 
27.88±1.06d 4.95±0.23 d 12.75±1.02a 10.57±0.32 a 
EAC+ AEDP 
(500mg/kg) 
24.85±0.76 c 6.3±0.16b 14.8±1.34 a 14.88±0.36 a 
 













Normal 22.05±1.77 8.68±0.3 23.13±0.24 17.73±0.14 
DAL control 37.23±2.12 3.57±0.18 5.52±0.52 6.8±0.23 
DAL + 5FU 18.43±0.45 8.25±0.33 21.65±0.85 16.8±0.22 
DAL+EEDP 
(250mg/kg) 




23.4±0.67 a 7.58±0.17 a 23.88±0.74 a 17.28±0.48 a 
DAL+ AEDP 
(250mg/kg) 
27.43±0.26 a 4.95±0.23 a 9.35±0.39 a 10.67±0.2 a 
DAL+ AEDP 
(500mg/kg) 
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of AEDP (250mg/kg) was not significant 
(P>0.05) on FSH restoration. 
The data is mentioned as mean ±  S. E. 
M.  n = 6. The data was evaluated by one way 
ANOVA by using Newman-Keul’s multiple 
comparison test. a-p<0.001, compared to the 
tumor control group, b- p<0.01, compared to 
the tumor control group, c-p<0.05, compared 
to the tumor control group, d- p>0.05 
compared to the tumor control group. 
The serum hormone levels in virgin 
female mice of DAL bearing mice were greatly 
altered (Table VI). An increased LH level was 
found in DAL control group mice. The 
continuous oral administration for 14 days with 
250 and 500 mg/kg of EEDP and AEDP 
significantly (p<0.001) restored the LH, FSH, 
E2 and progesterone level in female virgin mice 
bearing DAL cell line. 
The data is mentioned as mean ±  S. E. 
M.  n = 6. The data was evaluated by one way 
ANOVA by using Newman-Keul’s multiple 
comparison test. a-p<0.001, compared to the 
tumor control group. 
Metabolic syndrome (MS) plays a 
significant role in the progression of cancer 
which includes hypertriglyceridemia, low serum 
HDL level, etc. There is an epidemiological 
survey supporting that, a persons with MS are 
more prone to get colon cancer. Earlier 
preclinical animal study report revealed that soy 
and tea combination delayed the progression 
and the growth of breast and prostate tumour. 
The study also suggested that bioactive 
component which was present in soy and tea 
might have strong cancer prevention activity 
via the prevention of metabolic irregularities 
(Zhou et al., 2007). Based on the above 
hypothesis, this study has been conducted to 
evaluate the cancer development prevention 
and protection over the cancer associated 
metabolic syndrome in tumor bearing mice by 
using species of carnivorous plant Drosera in 
India. 
Tumor growth response was evaluated 
by change in body weight, PCV, tumor cell 
count, MST, and % ILS of cancer control mice 
was compared with extract treatment groups. 
In both DAL and EAC-bearing mice, ascites 
fluid volume increased progressively. This 
ascites fluids act as a nutritional supplement for 
tumor cell growth and development. This fluid 
volume was high which reflected their body 
weight in both DAL and EAC control mice 
(Malaya et al., 2004). Both the ethanol and 
aqueous extracts of DB, DP, and DI reduced 
the tumor growth and development of tumor in 
mice. 
Metabolism of glucose and its utilization 
are generally regulated by certain herbs and 
spices through their signalling pathways. High 
triglycerides level, low HDL and high LDL, 
elevated level of blood pressure, incidence of 
insulin resistance, and increased level of pro-
inflammatory markers and proteins in plasma 
are the characteristic for MS. A subject showing 
3 or more than three of the above 
characteristics plus insulin resistance is 
generally considered to have the MS. Plants 
with  polyphenols and flavonoids have 
antioxidant, anti-inflammatory and 
hypoglycaemic potential which play an 
important  role in reducing risk factors which 
are associated with development of metabolic 
syndrome (Kiran, 2013). In this study also, the 
plant genus Drosera contains plumbagin, 
naphthoquinones and flavonoids, which reduce 
the elevated blood sugar level in tumor bearing 
mice to normal. 
In cancer cachexia, reduction in body 
weight is due to exhaustion of body fat. 
Triglyceride, the major storage form of fat, is 
converted to glycerol and free fatty acids (FFA) 
by hydrolytic metabolism. This causes 
hyperlipidaemia and is associated with some 
tumors. In certain cancers, there is an 
association between weight loss and reduction 
of enzyme activity. When compared to normal 
person, cancer patient’s body energy 
requirements are provided by fat which are 
mobilized and oxidized in a greater extent 
which leads to low HDL and high triglycerides; 
these lipid abnormalities also can be observed 
in type 2 diabetes (Gallagher and LeRoith, 
2013, Douglas and Shaw, 1990). In the present 
study, an increased level of triglyceride and low 
level of HDL were observed in tumor control 
mice and were restored after continuous oral 
administration for 14 days with EEDP and 
AEDP. 
Researchers have also reported that there 
is an increase in risk of cancer development in 
those with increased level of endogenous sex 
hormones and gonadotrophic hormones with 
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respect to increase in number of receptor. 
Estrogen and progesterone are steroid 
hormones which support tumorigenesis 
process. Luteinizing hormone (LH) and follicle 
stimulating hormone (FSH) are involved in the 
regulation of steroidogenesis (Anup et al., 
2007). In this study EAC and DAL bearing 
virgin female mice showed altered hormone 
levels which were brought back to the normal 
by the extract treatment (except for the lower 
dose of AEDP). 
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